299 related articles for article (PubMed ID: 20608756)
21. The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C.
Metharom E; Galettis P; Manners S; Jelinek M; Liauw W; de Souza PL; Hoskins JM; Links M
Asia Pac J Clin Oncol; 2011 Mar; 7(1):65-74. PubMed ID: 21332653
[TBL] [Abstract][Full Text] [Related]
22. FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients.
Serdjebi C; Gagnière J; Desramé J; Fein F; Guimbaud R; François E; André T; Seitz JF; Montérymard C; Arsene D; Volet J; Abakar-Mahamat A; Lecomte T; Guerin-Meyer V; Legoux JL; Deplanque G; Guillet P; Ciccolini J; Lepage C; Dahan L
PLoS One; 2015; 10(8):e0135907. PubMed ID: 26308942
[TBL] [Abstract][Full Text] [Related]
23. Ethnic differences of two non-synonymous single nucleotide polymorphisms in CDA gene.
Sugiyama E; Lee SJ; Lee SS; Kim WY; Kim SR; Tohkin M; Hasegawa R; Okuda H; Kawamoto M; Kamatani N; Sawada J; Kaniwa N; Saito Y; Shin JG
Drug Metab Pharmacokinet; 2009; 24(6):553-6. PubMed ID: 20045991
[TBL] [Abstract][Full Text] [Related]
24. The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase.
Hodge LS; Taub ME; Tracy TS
Drug Metab Dispos; 2011 Nov; 39(11):2013-6. PubMed ID: 21832002
[TBL] [Abstract][Full Text] [Related]
25. Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy.
Ding X; Chen W; Fan H; Zhu B
Gene; 2015 Mar; 559(1):31-7. PubMed ID: 25582275
[TBL] [Abstract][Full Text] [Related]
26. Investigation of the pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in human plasma by liquid chromatography.
Yilmaz B; Kadioğlu YY; Aksoy Y
Anal Biochem; 2004 Sep; 332(2):234-7. PubMed ID: 15325290
[TBL] [Abstract][Full Text] [Related]
27. [Population pharmacokinetics of gemcitabine applied to personalize the dosage used in cancer patients].
Ramón-López A; Escudero-Ortiz V; Duart-Duart MJ; Pérez-Ruixo JJ; Valenzuela B
Farm Hosp; 2012; 36(4):194-206. PubMed ID: 22078546
[TBL] [Abstract][Full Text] [Related]
28. Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry.
Marangon E; Sala F; Caffo O; Galligioni E; D'Incalci M; Zucchetti M
J Mass Spectrom; 2008 Feb; 43(2):216-23. PubMed ID: 17941128
[TBL] [Abstract][Full Text] [Related]
29. Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates.
Kerr JZ; Berg SL; Dauser R; Nuchtern J; Egorin MJ; McGuffey L; Aleksic A; Blaney S
Cancer Chemother Pharmacol; 2001 May; 47(5):411-4. PubMed ID: 11391856
[TBL] [Abstract][Full Text] [Related]
30. Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine.
Zhou M; Ding YJ; Feng Y; Zhang QR; Xiang Y; Wan HY
Genet Mol Res; 2014 Apr; 13(2):3310-8. PubMed ID: 24841663
[TBL] [Abstract][Full Text] [Related]
31. Effect of its deaminated metabolite, 2',2'-difluorodeoxyuridine, on the transport and toxicity of gemcitabine in HeLa cells.
Hodge LS; Taub ME; Tracy TS
Biochem Pharmacol; 2011 Apr; 81(7):950-6. PubMed ID: 21291869
[TBL] [Abstract][Full Text] [Related]
32. New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine.
Veltkamp SA; Pluim D; van Eijndhoven MA; Bolijn MJ; Ong FH; Govindarajan R; Unadkat JD; Beijnen JH; Schellens JH
Mol Cancer Ther; 2008 Aug; 7(8):2415-25. PubMed ID: 18723487
[TBL] [Abstract][Full Text] [Related]
33. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Souzaki R; Tajiri T; Manabe T; Ohtsuka T; Tanaka M
Neoplasia; 2010 Oct; 12(10):807-17. PubMed ID: 20927319
[TBL] [Abstract][Full Text] [Related]
34. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
Giovannetti E; Mey V; Loni L; Nannizzi S; Barsanti G; Savarino G; Ricciardi S; Del Tacca M; Danesi R
Pharmacol Res; 2007 Apr; 55(4):343-9. PubMed ID: 17296311
[TBL] [Abstract][Full Text] [Related]
35. [Pharmacogenomic research for avoiding adverse reactions by anti-cancer drugs].
Saito Y
Yakugaku Zasshi; 2011 Feb; 131(2):239-46. PubMed ID: 21297369
[TBL] [Abstract][Full Text] [Related]
36. Determination of gemcitabine and its metabolite in human plasma using high-pressure liquid chromatography coupled with a diode array detector.
Lin NM; Zeng S; Ma SL; Fan Y; Zhong HJ; Fang L
Acta Pharmacol Sin; 2004 Dec; 25(12):1584-9. PubMed ID: 15569401
[TBL] [Abstract][Full Text] [Related]
37. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study.
Laufer M; Ramalingam S; Schoenberg MP; Haisfield-Wolf ME; Zuhowski EG; Trueheart IN; Eisenberger MA; Nativ O; Egorin MJ
J Clin Oncol; 2003 Feb; 21(4):697-703. PubMed ID: 12586808
[TBL] [Abstract][Full Text] [Related]
38. Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer.
Masumori N; Kunishima Y; Hirobe M; Takeuchi M; Takayanagi A; Tsukamoto T; Itoh T
Jpn J Clin Oncol; 2008 Mar; 38(3):182-5. PubMed ID: 18270381
[TBL] [Abstract][Full Text] [Related]
39. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.
Achiwa H; Oguri T; Sato S; Maeda H; Niimi T; Ueda R
Cancer Sci; 2004 Sep; 95(9):753-7. PubMed ID: 15471562
[TBL] [Abstract][Full Text] [Related]
40. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.
Kroep JR; Loves WJ; van der Wilt CL; Alvarez E; Talianidis I; Boven E; Braakhuis BJ; van Groeningen CJ; Pinedo HM; Peters GJ
Mol Cancer Ther; 2002 Apr; 1(6):371-6. PubMed ID: 12477049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
